Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Amgen presents Sjogren data: Amgen stock gets a 1.8-point test

Clinical trial results Dividend AI-generated analysis

πŸ“ˆ Amgen's Phase 3 OASIZ-301 trial showed a 1.8-point placebo gap in disease activity reduction at Week 48 for dazodalibep in Sjogren's disease.

πŸ“Š The four-week dosing regimen achieved a minus 5.6 point change in disease activity versus a minus 3.8 point change for the placebo group.

πŸ’§ Patients treated with dazodalibep experienced statistically significant improvements in patient-reported dryness symptoms compared to placebo.

πŸ’° Amgen declared a USD 2.52 per share dividend for Q4 2026, payable on December 11, 2026, to shareholders of record on November 20.

πŸ—“οΈ The company will present the OASIZ-301 late-breaking results as Abstract 22 at the American College of Rheumatology Convergence on November 11, 2026.

πŸ“‰ Amgen stock traded at EUR 401.05 on October 28, 2026, capturing market attention to the new clinical data and dividend announcement.

Bullish Signals
  • Amgen's Phase 3 OASIZ-301 trial demonstrated a statistically significant 1.8-point superiority over placebo in reducing disease activity at Week 48.
  • The dazodalibep treatment achieved a minus 5.6 point change in disease activity versus minus 3.8 points for placebo, indicating robust efficacy in Sjogren's disease.
  • The study reported statistically significant improvements in patient-reported dryness symptoms, addressing a key unmet need for the Sjogren's population.
  • Amgen declared a USD 2.52 per share quarterly dividend for Q4 2026, providing consistent cash returns to shareholders with a payment date of December 11.
Full Analysis
Amgen announced positive late-breaking clinical data for its Phase 3 OASIZ-301 trial evaluating dazodalibep in patients with Sjogren's disease. The study demonstrated a statistically significant reduction in disease activity compared to placebo, with the four-week dosing regimen showing a 1.8-point greater improvement at Week 48 versus the control group. The company reported that the least-squares mean change in disease activity was minus 5.6 points for the active treatment versus minus 3.8 points for placebo. Additionally, the trial observed statistically significant improvements in patient-reported dryness symptoms and a baseline ESSDAI score of 10.2. Amgen also declared a quarterly dividend of USD 2.52 per share for the fourth quarter of 2026, with a record date of November 20, 2026, and an expected payment date of December 11, 2026. The stock was trading at EUR 401.05 on October 28, 2026, reflecting investor attention to these dual developments. The company plans to present the OASIZ-301 results as Abstract 22 at the American College of Rheumatology Convergence on November 11, 2026. This presentation will provide further context alongside data for other assets like UPLIZNA and KRYSTEXXA during the conference.